Cholecystokinin and psychiatric disorders. Role in aetiology and potential of receptor antagonists in therapy

CNS Drugs

Volumn 8, Issue 2, 1997, Pages 134-152

  Shlik, Jakov ^a   Vasar, Eero ^a   Bradwejn, Jacques ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; AMINO ACID DERIVATIVE; BUCLADESINE; CERULETIDE; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ DERIVATIVE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; DIACYLGLYCEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE; LINTITRIPT; LORGLUMIDE; MESSENGER RNA; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; NEUROPEPTIDE; NEUROTRANSMITTER; PENTAGASTRIN; PHOSPHOLIPASE C; RADIOLIGAND; RECEPTOR SUBTYPE; TETRAGASTRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; ANXIETY NEUROSIS; AREA POSTREMA; AUTORADIOGRAPHY; BASAL GANGLION; BRAIN CORTEX; BRAIN REGION; CLINICAL TRIAL; DEPRESSION; GASTROINTESTINAL TRACT; HUMAN; HYPOTHALAMUS; LIMBIC SYSTEM; MENTAL DISEASE; MOLECULAR CLONING; NEUROBIOLOGY; NEUROPSYCHIATRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; TISSUE DISTRIBUTION;

EID: 8544264589     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708020-00005     Document Type: Review

References (197)

1. Rehfeld JF, Nielsen FC. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In: Bradwejn J, Vasar E, editors. Cholecystokinin and anxiety: from neuron to behavior. Austin: Springer Verlag-R.G. Landes Company, 1995: 33-56
2. Vanderhaegen J-J, Signeau JC, Gepts W. New peptide in vertebrate CNS reacting with antigastrin antibodies. Nature 1975; 257: 604-5
3. Dockray GJ. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 1976; 264: 568-70
4. Rehfeld JF. Neuronal cholecystokinin: one or multiple transmitters? J Neurochem 1985; 44: 1-10
5. Rehfeld JF, Hansen HF. Characterization of preprocholecystokinin products in the porcine cerebral cortex: evidence of different processing pathways. J Biol Chem 1986; 261: 5832-40
6. Rehfeld JF. CCK and anxiety: introduction In: Dourish CT, Cooper SJ, Iversen SD, et al., editors. Multiple cholecystokinin receptors in the CNS. New York: Oxford University Press, 1992: 117-20
7. Dockray GJ. CCK neurons and receptors in the CNS: introduction. In: Dourish CT, Cooper SJ, Iversen SD, et al., editors. Multiple cholecystokinin receptors in the CNS. New York: Oxford University Press. 1992: 3-7
8. Beinfeld MC, Meyer DK, Eskay RL, et al. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 1981; 212: 51-7
9. Savasta M, Palacios JM, Mengod G. Regional localization of the mRNA coding for the neuropeptide cholecystokinin in the rat brain studied by in situ hybridization. Neurosci Lett 1988; 93: 132-8
10. Vanderhaegen J-J, Schiffmann SN. Distribution of brain neuronal CCK: an in situ hybridization study. In: Dourish CT. Cooper SJ, Iversen SD, et al., editors. Multiple cholecystokinin receptors in the CNS. New York: Oxford University Press. 1992: 38-56
11. Pinget M, Strauss E, Yalow RS. Localization of cholecystokinin-like immunoreactivity in isolated nerve terminals. Proc Natl Acad Sci USA 1978; 75: 6324-6
12. Emson PC, Lee CM, Rehfeld JF. Cholecystokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro. Life Sci 1980; 26: 2157-63
13. Goltermann NR, Rehfeld JF, Rigaard-Petersen H. In vivo biosynthesis of cholecystokinin in rat cerebral cortex. J Biol Chem 1980; 255: 6181-5
14. Pinget M, Strauss E, Yalow RS. Release of cholecystokinin peptides from synaptosomal-enriched fraction of rat cerebral cortex. Life Sci 1979; 25: 339-42
15. Verhage M, Ghijsen WEJM, Nicholls DG, et al. Characterization of the release of cholecystokinin-8 from isolated nerve terminals and comparison with exocytosis of classical transmitters. J Neurochem 1991; 23: 1394-400
16. Moran TH, Robinson PH, Goldrich MS, et al. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986; 362: 175-9
17. Dodd J, Kelly JS. Excitation of CAI pyramidal neurons of the hippocampus by tetra- and octapeptide C-terminal fragments of cholecystokinin. J Physiol (Lond) 1979; 295: 61-2
18. Dodd J, Kelly JS. The actions of cholecystokinin and related peptides on pyramidal neurons of the mammalian hippocampus. Brain Res 1981; 205: 337-50
19. Boden P, Hill RG. Effects of cholecystokinin and related peptides on neuronal activity in the ventromedial nucleus of the rat hypothalamus. Br J Pharmacol 1988; 94: 246-52
20. Ishibashi S, Oomura Y, Okaijma T, et al. Cholecystokinin, motilin and secretin effects on the central nervous system. Physiol Behav 1979; 23: 401-3
21. 27-33 Brain Res 1987; 406: 130-5
22. Lopes da Silva FH, Witter MP, Boeijinga PH, et al. Anatomical organization and physiology of limbic cortex. Physiol Rev 1990; 70: 453-511
23. Peters A, Miller M, Kimerer LM. Cholecystokinin-like immuno-reactive neurons in rat cerebral cortex. Neuroscience 1983; 8: 431-48
24. Migaud M, Durieux C, Roques BP. Evidences of cholecystokinin octapeptide (CCK-8) uptake in rat cortex synaptosomal fractions [abstract]. J Neurochem 1993; 61 Suppl.: S83B
25. Hays SE, Beinfeld MC, Jensen RT, et al. Demonstration of a putative receptor site for cholecystokinin in rat brain. Neuropeptides 1980; 1: 53-62
26. Innis RB, Snyder SH. Distinct chnlecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 1980; 77: 6917-21
27. Saito AH, Sancaran H, Goldfine ID, et al. Cholecystokinin receptors in the brain: characterization and distribution. Science 1980; 208: 1155-6
28. Sancaran H, Goldfine ID, Deveney CW, et al. Binding of cholecystokinin in the brain: characterization and distribution. J Biol Chem 1980; 255: 1849-53
29. 3H]-L-364,718 membrane binding assays. Mol Pharmacol 1989; 36: 285-90
30. Gerhardt GA, Friedmann M, Brodic MS, et al. The effect of cholecystokinin (CCK-8) on dopamine-containing nerve terminals in the caudate nucleus and nucleus accumbens of the anaesthetized rat: in vivo electrochemical studies. Brain Res 1989; 499: 157-63
31. 3H]-dopamine efflux from rat nucleus accumbens. Neuropeptides 1989; 13: 43-50
32. 3H-MK-329. J Neurosci 1990; 10: 1070-81
33. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269: G628-46
34. Matozaki T, Sakomoto C, Nagano M, et al. G protein in stimulation of PI hydrolysis by CCK in isolated rat pancreatic acinar cells. Am J Physiol 1988; 255 (Endocrinol Metab 18): E652-9
35. Merrit JE, Taylor CW, Rubin PR, et al. Isomers of inositol triphosphate in exocrine pancreas. Biochem J 1985; 238: 825-9
36. Pang I-H, Sternweiss PC. Purification of unique α-subunits of GTP-binding regulatory proteins (G-proteins) by affinity chromatography with immobilized βγsubunits. J Biol Chem 1990; 265: 18707-12
37. Rhee SG, Kim H, Suh P-G, et al. Multiple forms of phosphoinositide-specific phospholipase C and different modes of activation. Biochem Soc Trans 1991; 19: 337-41
38. Smrcka AV, Sternweiss PC. Regulation of purified subtypes of phosphatidylinositol-specific phospholipase C by G protein α and βγ subunits. J Biol Chem 1993; 268: 9667-74
39. Taylor SJ, Chae HZ, Rhee SG, et al. Activation of beta I isoenzyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature 1991; 350: 516-8
40. 11 proteins in transfected Cos-7 cells. J Biol Chem 1992; 267: 1811-7
41. Berridge MJ. Inositol triphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 1987; 56: 159-93
42. 2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5,-triphosphate. Nature 1983; 306: 67-9
43. Williams JA, Yule DI. Stimulus-secretion coupling in pancreatic acinar cells. In: Go VLW, editor. The exocrine pancreas: biology, pathobiology and disease. 2nd ed. New York: Raven Press, 1993: 167-89
44. 2+ oscillations in response to cholecystokinin and carbachol hut not JMV-180 in rat acinar cells. J Biol Chem 1992; 267: 13830-50
45. Wakui M, Osipchuk YV, Petersen OH. Receptor-activated cytoplasmic Ca2+ spiking mediated by inositol triphosphate is due to Ca2+ induced Ca2+ release. Cell 1990; 63: 1025-32
46. Wukui M, Potter BVL, Petersen OH. Pulsatile mtracellular calcium release does not depend on fluctuations in inositol triphosphate concentration. Nature 1989; 339: 317-20
47. Pollo DA, Baldassare JJ, Honda T, et al. Effects of cholecystokinin and other secretagogues on isoforms of protein kinase C (PKC) in pancreatic acini. Biochim Biophys Acta 1990; 1224: 127-38
48. Roche S, Bali JP, Magous R. Involvement of a pertussis toxinsensitive G protein in the action of gastrin on gastric parietal cells. Biochim Biophys Acta 1990; 1055: 287-94
49. Tsunoda Y, Yodozawa S, Tashiro J. Heterogenous distribution of free calcium and propagation of calcium transient in gastric parietal cells revealed by digital imaging microscopy. J Histochem Cytochem 1989; 37: 999-1005
50. 2+], by secretagogue stimulation of canine gastric parietal cells. Am J Physiol 1992; 262 (Gastrointest Liver Physiol 25): G420-6
51. Zhang LJ, Lu XY, Han JS. Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatal-rat brain cells. Biochem J 1992; 285: 847-50
52. Galas MC, Bernard N, Martinez J. Pharmacological studies on CCK-B receptors in guinea pig synaptoneurosomes. Eur J Pharmacol 1992; 226: 321-5
53. Kaufmann R, Lindschau C, Schönberg T, et al. Type B cholecystokinin receptors on rat glioma C6 cells: binding studies and measurement of interacellular calcium mobilization. Brain Res 1994; 639: 109-14
54. Miyoshi R, Kito S, Nomoto T. Cholecystokinin increases intracellular Ca2+ concentration in cultured striatal neurons. Neuro-peptides 1991; 18: 115-9
55. Wank SA, Harkins R, Jensen RT, et al. Purification, molecular cloning, and functional expression of the cholecystokinin expression from rat pancreas. Proc Natl Acad Sci U S A 1992; 89: 3125-9
56. Ulrich CD, Ferber I, Holicky E, et al. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun 1993; 193: 204-11
57. Kopin AS, Lee Y-M, McBride EW, et al. Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992; 89: 3605-9
58. Lee Y-M, Beinborn M, McBride EW, et al. The human brain cholecystokinin-B/gastrin receptor. J Biol Chem 1993; 268: 8164-9
59. Huppi K, Siwarski D, Pisenga JR, et al. Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCKAR and CCKBR) in human and mouse. Genomics 1995; 25: 727-9
60. Talkad VD, Fortune KP, Pollo DA, et al. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc Natl Acad Sci USA 1994; 91: 1868-72
61. 3H]cholecystokinin as radioligand J Neurosci 1984; 4: 1021-33
62. Sekigushi R, Moroji T. A comparative study on characterization and distribution of cholecystokinin binding sites among the rat, mouse and guinea-pig brain. Brain Res 1986; 399: 271-81
63. Song I, Brown DR, Wilshire RN, et al. The human gastrin/cholecystokinin type b receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci USA 1993; 90: 9085-9
64. Honda T, Wada E, Battey JF, et al. Differential gene expression of CCKA and CCKB receptors in the rat brain. Mol Cell Neurosci 1993; 4: 143-54
65. Woodruff GN, Hughes J. Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 1991; 31: 469-501
66. Hahne WF, Jensen RT, Lemp GF, et al. Proglumid and benzotript: members of a different class of cholecystokinin receptors antagonists. Proc Natl Acad Sci U S A 1981; 78: 6304-8
67. Chang RSL, Lotti VJ. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 1986; 83: 4923-6
68. Rovati LC, Bani M, Macovec F, et al. Lorglumide and loxiglumide: two potent and specific antagonists of peripheral CCK. In: Bali J-P, Martinez J, editors. Gastrin and cholecystokinin: chemistry, physiology and pharmacology. Amsterdam: Elsevier, 1987: 45-8
69. Gully D, Frehel D, Marcy C, et al. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol 1993; 232: 13-9
70. Lotti VJ, Chang RSL. A new and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989; 162: 273-80
71. Showell GA, Bourrain S, Neduveil JG, et al. L-740,093: high affinity and potent, water soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonist containing a cationic solubilizing group. J Med Chem 1994; 37: 719-21
72. Hughes J, Boden P, Costall B, et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990; 87: 6728-32
73. Howbert JJ, Lobb KL, Brown RF, et al. A novel scries of non-peptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism. In: Dourish CT, Cooper SJ, Iversen SD, et al., editors. Multiple cholecystokinin receptors in the CNS. New York: Oxford University Press, 1992: 28-37
74. Fekete M, Lengyel A, Hegedues B, et al. Further analysis of the effects of cholecystokinin octapeptide on avoidance behavior in rats. Eur J Pharmacol 1984; 98: 79-91
75. Della-Fera MA, Baile CA. Cholecystokinin octapeptide: continuous picomole injections into the cerebral ventricles of sheep suppress feeding. Science 1979; 206: 471-3
76. Csonka E, Fekete M, Nagy G, et al. Anxiogenic effect of cholecystokinin in rats. In: Penke B, Török A, editors. Peptides: chemistry, biology, interactions with proteins. New York: Walter de Gruyter & Co, 1988: 249-52
77. Harro J, Pöld M, Vasar E. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunyn Schmiedebergs Arch Pharmacol 1990; 341: 62-7
78. Harro J, Vasar E. Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 1991; 193: 379-81
79. Singh L, Lewis AS, Field MJ, el al. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci U S A 1991; 88: 1130-3
80. Palmour RM, Bradwejn J, Ervin FR. The anxiogenic effects of CCK-4 in monkeys are reduced by CCKB antagonists, benzodiazepines or adenosine A2 agonists. Eur Neuropsychopharmacol 1992; 2: 193-5
81. Biro E, Sarnyai Z, Penke B, et al. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology 1993; 57: 340-5
82. Rex A, Barth T, Voigt J-P, et al. Effect of cholecystokinin tetrapeptide and sulfated cholecystokinin tetrapeptide in rat models of anxiety. Neurosci Lett 1994; 172: 139-42
83. Rex A, Fink H, Mardsen CA. Effects of Boc-CCK-4 and L-365,260 on cortical 5-HT release in guinea-pigs on exposure to elevated plus maze. Neuropharmacology 1994; 33: 559-65
84. Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993; 14: 244-9
85. Swerdlow NR, van der Kooy D, Koob GF, et al. Cholecystokinin produces conditioned place-aversions, not place-preferences, in food-deprived rats: evidence against involvement in satiety. Life Sci 1983; 32: 2087-93
86. Bayley PJ, Dawson GR. The effect of i.v. administration of CCK-4 on lever pressing rates of rats on an operant random interval schedule [abstract]. Br J Pharmacol 1993; 108 Suppl.: 244P
87. Rupnjak NMJ, Schaffer L, Siegl P, et al. Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys. Neuropeptides 1993; 25: 115-9
88. Harro J, Vasar E. Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour. Neurosci Biobehav Rev 1991; 15: 473-7
89. Crawley JN. Subtype selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J Neurosci 1992; 12: 3380-91
90. Vasar E, Lang A, Harro J, et al. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus maze. Neuropharmacology 1994; 33: 729-35
91. Dawson GR, Rupnjak NMJ, Iversen SD, et al. Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology 1995; 121: 109-17
92. Hökfelt T. Neuropeptide in perspective: the last ten years. Neuron 1991; 7: 867-79
93. Harro J, Pold M, Vasar E, et al. The role of CCK-ergic mechanisms in the regulation of emotional behaviour in rodents. J Higher Nervous Act 1989; 39: 877-83
94. Vasar E, Harro J, Pold M, et al. CCK receptors and anxiety in rats. In: Dourish CT, Cooper SJ, Iversen SD, et al., editors. Multiple cholecystokinin receptors in the CNS. New York: Oxford University Press, 1992: 143-8
95. Pratt JA, Brett RR. The benzodiazepine receptor inverse agonist FG 7142 induces cholecystokinin gene expression in rat brain. Neurosci Lett 1995; 184: 197-200
96. 8 and benzodiazepine receptor characteristics. Behav Brain Res 1990; 39: 63-71
97. Vasar E, Peuranen E, Harro J, et al. Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 96-101
98. Harro J. Studies on the brain cholecystokinin receptors and behaviour (dissertation). Acta Universitas Upsaliensis vol 421. Uppsala: Uppsala University Press, 1993
99. Palasevic S, Bednar I, Qureshi GA, et al. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 1993; 5: 225-8
100. Harro J, Lofberg C, Rehfeld JF, et al. Cholecystokinin peptides and receptors in the rat-brain during stress. Naunyn Schmiedebergs Arch Pharmacol 1996; 354 (1): 59-66
101. Powell KR, Barett JE. Evaluation of the effects of PD 134308 (CI-988) a CCK-B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 1991; 19 Suppl.; 75-8
102. Dooley DJ, Klamt I. Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the 4-plate lest. Psychopharmacology 1991; 112: 452-4
103. Hökfelt T, Skirboll LR, Rehfeld JF, et al. A subpopulalion of mescncephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 1980; 5: 2093-142
104. Vanderhaegen J-J, Lotstra F, Demey J, et al. Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rats. Proc Natl Acad Sci U S A 1980; 77: 1190-4
105. Wise RA, Rompré PP. Brain dopamine and reward. Annu Rev Psychol 1989; 40: 191-225
106. 2 dopaminergic receptors in the emotional and motivational responses induced by injection of CCK-8 in the posterior part of the rat nucleus accumbens. Brain Res 1991; 617: 181-8
107. Bradwejn J, de Montigny C. Benzodiazepines antagonize cholecyslokinin-induced activation of rat hippocampal neurons. Nature 1984; 112: 363-4
108. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 1989; 46: 511-7
109. Bradwejn J, Koszycki D, Meterissian G. Cholccystokinin tetra-peptide in panic disorder. Can J Psychiatry 1990; 35: 83-5
110. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
111. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 1991; 48: 603-10
112. Bradwejn J, Koszycki D, Bourin M. Comparison of the effects of cholecystokinin and carbon dioxide in healthy volunteers. Eur Neuropsychopharmacol 1991; 1: 137-41
113. 2-induced panic attacks in PD. Prog Neuropsych Biol Psychiatry 1991; 15: 237-9
114. Abelson JL, Nesse RM, Vinik A. Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry 1991; 29: 1220-3
115. Van Megen HJGM, Westenberg HGM, den Boer JA, et al. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology (Berl) 1994; 114: 449-55
116. Lydiard RB, Ballenger JC, Laraia MT, et al. CSF: cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 1992; 149: 691-3
117. Brambilla F, Bellodi L, Perna G, et al. Lymphocyte cholecystokinin concentrations in panic disorder. Am J Psychiatry 1993; 150: 1111-3
118. Kennedy JL, Koszycki D, Katzman MA, et al. CCK-B receptor gene alleles associated with panic disorder (abstract]. American Psychiatric Association Annual Meeting: 1997 May 17-22: San Diego, NR615
119. Bradwejn J. Cholecystokinin and panic disorder. In: Bradwejn J, Vasar H, editors. Cholecystokinin and anxiety: from neuron to behavior. Austin. Springer Verlag-R.G.Landes Company. 1995: 73-86
120. Bradwejn J, Koszycki D. Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients. Am J Psychiatry 1994; 151: 261-3
121. van Megen HJGM. Westenberg HGM, den Boer JA. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 1997; 129: 357-64
122. Shlik J, Aluoja A, Vasar V, et al. Effects of citalopram treatment on behavioral, cardiovascular and neuroendocrine response to CCK-4 challenge in panic disorder patients [abstract]. American Psychiatric Association Annual Meeting: 1997 May 17-22: San Diego, NR145
123. Bradwejn J, Cöuetoux du Tetre A, van Megen HJGM, et al. The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365,260. a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994; 51: 486-93
124. Lines C, Challenor J, Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365.260. Br J Clin Pharmacol 1995; 39(3): 235-42
125. Bradwejn J, Paradis M, Koszycki D, et al. The effects of CI-988 on CCK-4 panic in healthy volunteers. Biol Psychiatry 1995; 38: 742-6
126. Van Megen HJGM, Westenberg HGM, den Boer JA, et al. The cholecystokinin-B receptor antagonists CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology 1997; 129: 243-8
127. Cowley DS, Adams JB, Pyke RE, et al. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Biol Psychiatry 1996; 40: 550-2
128. van Megen HJ, Westenberg HG, den Boer JA. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients. Biol Psychiatry 1996; 40: 804-6
129. Grasing K, Murphy MG, Lin J, et al. Human pharmacokinetics and tolerability of L-365.260. a novel cholecystokinin-B antagonist. J Clin Pharmacol 1996; 36: 292-300
130. Kramer MS, Cutler NR, Ballenger JC, et al. A placebo-controlled trial of L-365.260. a CCKB antagonist, in panic disorder. Biol Psychiatry 1995; 37: 462-6
131. Le Melledo J-M, Bradwejn J, Koszycki D, et al. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry 1995; 52: 605-6
132. Coupland NJ, Nutt DJ. Neurobiology of anxiety and panic. In: Bradwejn J, Vasar E, editors. Cholecystokinin and anxiety: from neuron to behavior. Austin: Springer Verlag-R.G. Landes Company, 1995: 1-32
133. McCann GD, State SO, Geraci M, et al. A comparison of the effects of intravenous pentagastrin on patients with social phobia, punic disorder and healthy controls. Neuropsychopharmacology 1997; 16: 229-37
134. De Leeuw AS, den Boer JA, Slaap BR, et al. Pentagastrin has panic inducing properties in obsessive-compulsive disorder. Psychopharmacology 1996; 126(4): 339-44
135. Brawman-Mintzer O, Lydiard RB, Bradwejn J, et al. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 1997; 5: 700-2
136. Adams JB, Pyke RE, Costa J, et al. A double-blind, placebo-controlled study of a CCK-B receptor antagonist. CI-988. in patients with generalized anxiety disorder. J Clin Psycho-pharmacol 1995; 15: 428-34
137. B receptor antagonists by ex vivo binding. Eur J Pharmacol 1994; 253: 237-44
138. Harro J, Vasar E, Koszycki D, et al. Cholecystokinin in panic and anxiety disorders. In: Panksepp J, editor. Advances in biological psychiatry. Vol. I. Greenwich (CT): JAI Press Inc., 1995: 235-62
139. Crawley JN. Interactions between cholecystokinin and other neurotransmitter systems. In: Bradwejn J, Vasar E, editors. Cholecystokinin and anxiety: from neuron to behavior. Austin: Springer Verlag-R.G.Landes Company. 1995: 101-26
140. Daugé V, Roques BP. Opioid and CCK systems in anxiety and reward. In: Bradwejn J, Vasar E, editors. Cholecystokinin and anxiety: from neuron to behavior. Austin: Springer Verlag-R.G. Landes Company, 1995: 151-71
141. Derrien M, McCort-Tranchepain I, Ducos B, et al. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 1994; 49 (1): 133-41
142. Léna I, Daugé V, Roques BP, et al. Distinct pharmacological profiles of two CCK-B agonists: further evidence of rat CCK-B receptor subsites [abstract]. Soc Neurosci Abstr 1996; 22 (1): 78
143. Harper EA, Roberts SP, Shankley NP, et al. Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br J Pharmacol 1996; 118 (7): 1717-26
144. Gorman JM, Liebowitz MR, Ever AJ, et al. The neuroanatomical hypothesis of panic disorder. Am J Psychiatry 1989; 146 (2): 148-61
145. Denavit-Saubié M, Hurle MA, Morin-Surum MP, et al. The effects of cholecystokinin-8 in the nucleus tractus solitarius. In: Vanderhaegen JJ, Crawley JN, editors. Neuronal cholecystokinin. New York: The New York Academy of Sciences, 1985: 375-84
146. Gerner RH, Yumuda T, Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982; 238: 298-302
147. Gjerris A, Rafaelsen OJ, Vendsborg P, et al. Vasoactive intestinal neuropeptide decreased in cerehrospinal fluid (CSF) in atypical depression. J Affect Disord 1984; 7: 325-37
148. Lotstra F, Verbanck PMP, Gilles C, et al. Reduced cholecystokinin levels in cerebrospinal fluid of Parkinsonian and schizophrenic patients. Ann N Y Acad Sci 1985; 448: 507-17
149. Rafaelsen OJ, Gjerris A. Neuropeptides in the cerebrospinal fluid (CSF) in psychiatric disorders. Prog Neuropsych Biol Psychiatry 1985; 9: 533-8
150. Verbanck PMP, Lotstra F, Gilles C, et al. Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disorders. Life Sci 1984; 34: 67-72
151. Harro J, Mareusson J, Oreland L. Alterations in brain cholecystokinin receptors in suicide victims. Eur Neuropsychopharmacol 1992; 27: 57-63
152. Brodin K, Rosen A, Iwarsson K, et al. Increased levels of substance P and cholecystokinin in rat cerebral cortex following repeated electroconvulsive shock and subchronic treatment with a serotonin uptake inhibitor. Acta Physiol Scand 1989; 136: 613-4
153. Kelly JP, Leonard BE. An examination of CI 988 in 3 animal models of depression [abstract]. J Psychopharmacol 1992; 6 Suppl.: A14
154. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatment. Nature 1977; 266: 730-2
155. Van Riezen HV, Leonard BE, Effect of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 1990; 47: 21-37
156. Derrien M, Durieux C, Roques BP. Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br J Pharmacol 1994; 111: 956-60
157. B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology 1995; 120: 400-8
158. Hernando F, Fuentes JA, Roques BP, et al. The CCK-B receptor antagonist. L-365.260, elicits antidepressant-type effects in the forced-swim test in mice. Eur J Pharmacol 1994; 261: 257-63
159. Crawley JN, Corwin RL. Biological actions of Cholecystokinin. Peptides 1994; 15 (4): 731-55
160. Wang RY. Cholecystokinin, dopamine. and schizophrenia: recent progress and current problems. Ann N Y Acad Sci 1988; 89: 3125-9
161. Fuxe K, Andersson K, Locatelli V, et al. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the brain following intraventricular injection. Eur J Pharmacol 1980; 67: 329-31
162. 1-receptor stimulation reduces neostriatal Cholecystokinin release. Fur J Pharmacol 1984; 104: 387-8
163. Voigt M, Wang RY, Westfall TC. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro. J Pharmacol Exp Ther 1986; 237: 147-53
164. Hommer DW, Skirboll LR. Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons. Eur J Pharmacol 1983; 91: 151-2
165. Crawley JN, Stivers JA, Blumstein LK, et al. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence. J Neurosci 1985; 5: 1972-83
166. Vaccarino FJ, Rankin J. Nucleus accumbens Cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behav Neurosci 1989; 103: 831-6
167. Virgo L, Humphries C, Mortimer A, et al. Cholecystokinin messenger RNA deficit in frontal cortex and temporal cerebral cortex in schizophrenia. Biol Psychiatry 1995; 37: 694-701
168. 125l|-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine and ventral tegmental lesions. Life Sci 1983; 32: 871-8
169. Suzuki T, Moroji T, Hori T, et al. Autoradiographic localization of CCK-8 binding sites in the rat brain: effects of chronic metamphetamine on these sites. Biol Psychiatry 1993; 34: 781-90
170. Dumbrille-Ross A, Seeman P. Dopamine receptor elevation by Cholecystokinin. Peptides 1984; 5: 1207-12
171. Cohen SL, Stivers JA, Blumstein LK, et al. Cholecystokinin octapeptide effects on conditioned avoidance behavior, stereotypy and catalepsy. Eur J Pharmacol 1982; 83: 213-22
172. 8 related peptides resembles that of antipsychotic drugs. Eur J Pharmacol 1983; 93: 63-78
173. Zetler G. Caerulein and its analogues: neuropharmacological properties. Peptides 1985; 6 Suppl. 3: 33-46
174. Vasar E, Allikmets L, Ryzhov I, et al. Interspecies differences in the behavioural effects of cacrulein. an agonist of CCK-8 receptors, in mice and rats. Bull Exp Biol Med 1988; 105: 168-70
175. Britton DR, Curzon P, Yahiro L, et al. Evaluation of a stable CCK agonist (A68552) in conditioned avoidance responding in mice, rats, and primates: comparison with typical and atypical antipsychotics. Pharmacol Biochem Behav 1992; 43: 369-76
176. Lang A, Harro J, Soosaar A, et al. Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn Schmiedebergs Arch Pharmacol 1995; 351: 363-70
177. Csernansky JG, Glick S, Mellentin J. Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function. Psychopharmacology 1987; 91: 440-4
178. Wettstein JG, Grouhel A, Earley B, et al. Unique behavioral profiles of CCK antagonists in rats [abstract]. Soc Neurosci Abstr 1992; 18: 815
179. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3: 1607-19
180. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Life Sci 1983; 221: 1054-7
181. Rasmussen K, Stockton ME, Czachura JF, et al. Cholecystokinin and schizophrenia: the selective CCK-B antagonist LY 262691 decreases midbrain dopamine unit activity. Eur J Pharmacol 1991; 209: 749-53
182. Rasmussen K, Czachura JF, Stockton ME, et al. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J Pharmacol Exp Ther 1993; 264: 480-8
183. Stockton ME, Howbert JJ, Rasmussen K. Localization of receptors mediating the effects of the selective CCK-B antagonist LY262291 on A9 and A10 dopamine cells: lesion and microinjection studies [abstract]. Soc Neurosci Abstr 1992; 18: 278
184. Chiodo LA, Bunney BS. Population response of midbrain dopaminergic neurons to neuroleptics: further studies on time course and nondopaminergic influences. J Neurosci 1987; 7: 629-33
185. Jiang LH, Kasser RJ, Wang RY. Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons. Brain Res 1988; 473: 165-8
186. Minabe Y, Ashby CR, Wang RY. The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effects of chronic clozapine and haloperidol on midbrain dopamine neurons. Brain Res 1991; 549: 151-4
187. Zhang J, Chiodo LA, Freeman AS. Effects of the CCK-A receptor antagonist CR 1409 on the activity of rat midbrain dopamine neurons. Peptides 1991; 12: 339-43
188. Innis R, Bunney BS, Charney DS, et al. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? J Psychiatr Res 1986; 18: 1-7
189. Hicks PB, Vinogradov S, Riney SJ, et al. A preliminary doseranging trial of proglumide for the treatment of refractory schizophrenics. J Clin Psychopharmacol 1989; 9: 209-12
190. Lotstra F, Verbanck PMP, Mendelewicz J, et al. No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study. Biol Psychiatry 1984; 19: 877-82
191. Tamminga CA, Littman RL, Alphs LD, et al. Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology 1986; 88: 387-91
192. Ferrier IN, Roberts GW, Crow TJ, et al. Reduced cholecystokininlike and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci 1983; 33: 475-82
193. Ferrier IN, Crow TJ, Farmery SM, et al. Reduced cholecystokinin levels in the limbic lobe in schizophrenia. Ann N Y Acad Sci 1985; 448: 495-506
194. Roberts GW, Ferrier IN, Lee Y, et al. Peptides, the limbic lobe and schizophrenia. Brain Res 1983; 288: 199-211
195. Carruthers B, Dawbarn D, De Quidt M, et al. Changes in neuropeptide content of amygdala in schizophrenia [abstract]. Br J Pharmacol 1984; 81 Suppl.: 190P
196. Farmery SM, Owen F, Poulter M, et al. Reduced high activity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci 1985; 36: 473-7
197. Carver DL, Beinfeld MC, Yao JK. Cholecystokinin, dopamine and schizophrenia. Psychol Bull 1991; 26: 377-91